PTC Therapeutics, Inc. is a biopharmaceutical company. It is focused on the discovery and development of orally administered, small-molecule drugs for genetic disorders, oncology and infectious disease. PTC Therapeutics, Inc. is based in South Plainfield, United States.
| Revenue (Most Recent Fiscal Year) | $1.73B |
| Net Income (Most Recent Fiscal Year) | $682.64M |
| PE Ratio (Current Year Earnings Estimate) | 59.52 |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | 2.15 |
| Price to Sales Ratio (Trailing 12 Months) | 5.75 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 7.92 |
| Pre-Tax Margin (Trailing 12 Months) | -6.65% |
| Net Margin (Trailing 12 Months) | -3.80% |
| Return on Equity (Trailing 12 Months) | -362.45% |
| Return on Assets (Trailing 12 Months) | -1.32% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.39 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.28 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | 0.94 |
| Book Value per Share (Most Recent Fiscal Quarter) | $-1.98 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.92 |
| Earnings per Share (Most Recent Fiscal Year) | $7.78 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.58 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 83.46M |
| Free Float | 79.04M |
| Market Capitalization | $5.80B |
| Average Volume (Last 20 Days) | 0.86M |
| Beta (Past 60 Months) | 0.55 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 5.30% |
| Percentage Held By Institutions (Latest 13F Reports) | -- |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |